Abstract: SA-PO0573
Kidney Stones in ADPKD: Epidemiology and Metabolic Risk Factors
Session Information
- Cystic Kidney Diseases: Clinical Research
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases
Authors
- Noruzi, Anahita, Erasmus MC, Rotterdam, ZH, Netherlands
- Xue, Laixi, Erasmus MC, Rotterdam, ZH, Netherlands
- Meijer, Esther, Universitair Medisch Centrum Groningen, Groningen, GR, Netherlands
- van Gastel, Maatje D.A., Universitair Medisch Centrum Groningen, Groningen, GR, Netherlands
- Hoorn, Ewout J., Erasmus MC, Rotterdam, ZH, Netherlands
- Gansevoort, Ron T., Universitair Medisch Centrum Groningen, Groningen, GR, Netherlands
- Chapman, Arlene B., The University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
- Salih, Mahdi, Erasmus MC, Rotterdam, ZH, Netherlands
Background
The prevalence of kidney stones (KS) in the general population is estimated at 10%. Autosomal dominant polycystic kidney disease (ADPKD) is thought to increase the risk of KS due to anatomic abnormalities and metabolic derangements affecting urine composition. However, clinical data remain limited and inconsistent. We investigated the epidemiology of KS and associated clinical and metabolic factors in two prospective observational ADPKD cohorts.
Methods
We analyzed data from the Dutch DIPAK cohort and the US-based CRISP cohort. Patients with a history of KS at baseline were classified as having prevalent kidney stone disease, while those who reported kidney stone symptoms during follow-up were classified as having incident stones. In DIPAK, 24-hour urine collections were used to calculate relative supersaturation ratios (RSR).
Results
At baseline, 68 of 698 patients (9.8%) in the DIPAK and 32 of 241 (13.3%) in the CRISP cohort reported a history of KS. In both cohorts, individuals with a history of KS were older, had higher BMI, larger total kidney volumes (htTKV) and lower eGFR. In DIPAK, these associations remained consistent across eGFR subgroups. Additionally, KS patients in CRISP showed a greater annual rate of increase in htTKV. BMI was independently associated with KS (OR 1.10, 95%CI 1.03–1.17). During a median follow-up of 5.1 years in DIPAK, 9 patients developed incident KS (incidence rate 0.40 per 100 person-years). The incidence in CRISP was similar (0.60 per 100 person-years). Incident cases in DIPAK had significantly lower baseline urinary pH (5.8 ± 0.8 vs. 6.3 ± 0.6) and potassium excretion (57 ± 12 vs. 76 ± 36 mmol/day), while calcium, oxalate and citrate excretion as well as RSR were similar between patients with and without KS. Similarly, kidney function decline did not differ.
Conclusion
In two independent ADPKD cohorts, the prevalence and incidence of KS are lower than previously reported in ADPKD and similar as known in the general population. Higher BMI was independently associated with a history of KS. Incident stone formers had lower baseline urinary pH and potassium excretion, suggesting a possible relationship with diet. Better understanding of these factors may help reduce stone risk in ADPKD.
Funding
- Government Support – Non-U.S.